Diabetes in Chronic Kidney Disease (Diabetic Kidney Disease)

1. Pathophysiology

A. Hemodynamic Mechanisms

• RAAS activation: Hyperglycemia activates renin-angiotensin-aldosterone system (RAAS), raising angiotensin II, which preferentially constricts the efferent arteriole, raising intraglomerular pressure.
• SGLT1/SGLT2 upregulation: Diabetes upregulates sodium-glucose cotransporters in the proximal tubule, leading to increased glucose and sodium reabsorption. This decreases distal delivery of sodium to the macula densa, blunting tubuloglomerular feedback and sustaining hyperfiltration.
• Insulin-like growth factor (IGF-1) and growth hormone: Elevated in early diabetes; stimulate renal hypertrophy and GFR increase.
• Kallikrein-kinin system (KKS): In early/moderate hyperglycemia, renal kallikrein excretion is elevated, correlating with increased RBF and GFR.

B. Metabolic Mechanisms

• Advanced glycation end products (AGEs): Glucose non-enzymatically glycates proteins, forming AGEs that crosslink collagen in the GBM, increase glomerular permeability, and stimulate mesangial matrix expansion via TGF-β.
• Reactive oxygen species (ROS): Hyperglycemia drives mitochondrial ROS production (via polyol pathway, protein kinase C activation, AGE accumulation), promoting oxidative stress, inflammation, and fibrosis.
• TGF-β: Key profibrotic cytokine, stimulates mesangial cell production of extracellular matrix, collagen IV, and fibronectin.
• Dyslipidemia: Contributes to glomerular injury, especially relevant in type 2 diabetes.
• Tubular metabolic reprogramming: Adaptive and maladaptive shifts in tubular metabolism (fatty acid oxidation, glycolysis) contribute to both diabetic and non-diabetic CKD progression. (Brenner & Rector's The Kidney)

C. Genetic Factors

• ACE gene polymorphism (D allele / DD genotype): Associated with higher ACE activity in renal tissues and increased susceptibility to ESKD.
• IL-10 -1082G/A (AA genotype): ~2.5-fold higher susceptibility to diabetic nephropathy.
• IL-6 gene polymorphisms (rs1800796, rs1524107): Predict nephropathy progression.
• ACACB gene (acetyl coenzyme A carboxylase β): Related to proinflammatory responses in renal tubular cells.
• ICAM1 K469E polymorphism: Associated with DKD in Asian populations. (Brenner & Rector's The Kidney, 2-Volume Set)

D. Structural/Histological Changes (Pathology)

• GBM thickening: Detectable on EM within a few years of diabetes onset, even before functional changes.
• Diffuse mesangial sclerosis: Increase in mesangial matrix with mesangial cell proliferation and BM thickening; found after >10 years of disease; leads to nephrotic syndrome when severe.
• Nodular glomerulosclerosis (Kimmelstiel-Wilson lesion): Ball-like deposits of laminated matrix in the periphery of glomeruli. Present in 15-30% of patients with long-term diabetes. Virtually pathognomonic of diabetes. There is a significant correlation between KW nodules and diabetic retinopathy.

• Hyaline arteriolosclerosis affecting both afferent and efferent arterioles - efferent involvement is virtually unique to diabetes.
• Atherosclerosis; vascular compromise leads to nephrosclerosis (finely granular cortical surface).

2. Clinical Features and Natural History

Stages of Diabetic Nephropathy (Classic Mogensen Classification)

• Microalbuminuria appears 5-10 years after diabetes onset; classically progresses over 5-10 years to overt proteinuria and declining GFR.
• Contemporary caveat: Up to 24% of T1DM and 50% of T2DM patients with CKD may be normoalbuminuric - the classic albuminuric progression is not universal.
• Proteinuria in DKD can range from 500 mg to 25 g/24h.
• GFR decline rate: 1.8-14 mL/min/year depending on treatment and risk factors. (Harrison's Principles of Internal Medicine 22E, 2025)

Key Clinical Associations

• Retinopathy: Present in >90% of T1DM with nephropathy (vs. ~60% in T2DM). Absence of retinopathy in a T1DM patient with proteinuria should prompt biopsy to exclude another diagnosis.
• Enlarged kidneys may persist even in advanced DKD (unlike most other causes of CKD where kidneys shrink).
• Hypertension: Nearly universal; accelerates progression.
• Nephrotic syndrome: When glomerulosclerosis is severe - edema, hypoalbuminemia, heavy proteinuria.
• Cardiovascular disease: Albuminuria and reduced GFR are both independent risk factors for CV events; many patients die of CV disease before reaching ESKD.
• Risk factors for CKD in T2DM: Retinopathy/neuropathy, age, BP ≥140/80 mmHg, cardiovascular disease history, longer duration of diabetes. (Fuster and Hurst's The Heart, 15th Edition; Harrison's)

3. Management

A. Glycemic Control

• Target HbA1c: Generally ~7% (individualize - more lenient in advanced CKD/elderly due to hypoglycemia risk).
• DCCT (T1DM) and UKPDS (T2DM) both demonstrated that strict glycemic control prevents development and progression of microalbuminuria.
• Metformin: First-line in T2DM; dose-reduce or stop at eGFR <30-45 mL/min/1.73m² (risk of lactic acidosis).
• Insulin: Dose reduction needed as eGFR falls (reduced renal clearance of insulin - paradoxically, insulin requirements may decrease in advanced CKD).
• Sulfonylureas: Use with caution - gliquidone or glipizide preferred in CKD; avoid glibenclamide (active metabolite accumulates). Hypoglycemia risk increases.
• DPP-4 inhibitors: Dose-adjusted for eGFR; generally safe.
• GLP-1 receptor agonists: See below.
• SGLT2 inhibitors: See below.

B. RAAS Blockade (Cornerstone of Therapy)

• ACE inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs) are first-line anti-proteinuric and renoprotective agents in DKD regardless of blood pressure.
  • Reduce intraglomerular pressure by dilating the efferent arteriole.
  • Reduce proteinuria and slow GFR decline.
  • The ACE gene D allele (high ACE activity) genotype predicts greater benefit.
• Dual ACEi + ARB: Not recommended due to increased risk of hyperkalemia and AKI without additional benefit (ONTARGET trial data).
• ACEi/ARB are contraindicated in pregnancy (second/third trimester - birth defects including renal tubular dysplasia, hypocalvaria).

C. Mineralocorticoid Receptor Antagonists (MRA)

• Spironolactone / Eplerenone: Reduce albuminuria in DKD; use limited by hyperkalemia, especially with ACEi/ARB.
• Finerenone (novel non-steroidal, selective MRA): Attenuates albuminuria; in FIDELIO-DKD (5734 T2DM patients, eGFR 25-75 mL/min/1.73m², albuminuria):
  • 18% lower risk of kidney failure, ≥40% eGFR decline, or kidney death vs. placebo.
  • 14% reduction in CV outcomes.
  • Lower hyperkalemia rate than steroidal MRAs (2.3% discontinuation vs. 0.9% placebo).
  • Target: T2DM patients with moderately increased albuminuria + impaired eGFR, or severely increased albuminuria. (NKF Primer on Kidney Diseases 8e; Comprehensive Clinical Nephrology 7th Ed.)

D. SGLT2 Inhibitors (Paradigm-Shifting Therapy)

• CREDENCE (Canagliflozin, eGFR ≥30 to <90, T2DM + DKD): 33% reduction in risk of kidney replacement therapy, doubling of serum creatinine, and death from kidney insufficiency; also reduced major CV events and heart failure hospitalization.
• DAPA-CKD (Dapagliflozin, eGFR 25-75 mL/min, including non-diabetic CKD): Reduced sustained ≥50% eGFR decline, ESKD, and CV/kidney death. Benefit seen even in non-diabetic CKD.
• EMPA-KIDNEY, CREDENCE, and DAPA-CKD data collectively support SGLT2 inhibitors across eGFR as low as 25 mL/min/1.73m² for initiation, with continuation even if eGFR falls further after starting.
• Recommended for T2DM with CKD + albuminuria in addition to RAAS blockade. (NKF Primer 8e; Comprehensive Clinical Nephrology 7th Ed.)

E. GLP-1 Receptor Agonists

• Reduce HbA1c, body weight, and blood pressure.
• Cardiorenal outcome trials (LEADER - liraglutide; SUSTAIN-6 - semaglutide): Significant reductions in new/worsening nephropathy.
• A 2025 Cochrane systematic review (PMID 39963952) confirmed benefits of GLP-1 RAs for people with both CKD and diabetes.
• Preferred agents in T2DM + established CV disease or CKD, alongside or after SGLT2 inhibitors.
• Dose adjustment generally not required for renal impairment (except exenatide - avoid if eGFR <30).

F. Blood Pressure Control

• Target BP: <130/80 mmHg in DKD with albuminuria (ADA/KDIGO).
• ACEi/ARB as first-line; add amlodipine or diuretics as needed.
• Dihydropyridine CCBs are preferred over non-dihydropyridines when added to RAAS blockade.
• Loop diuretics (furosemide) for volume overload in advanced CKD; thiazides lose efficacy at eGFR <30.

G. Lipid Management

• CKD (like diabetes) is a cardiovascular risk equivalent.
• LDL targets: <55 mg/dL if eGFR <30 mL/min/1.73m²; <70 mg/dL in CKD stage 3.
• SHARP trial: Simvastatin 20mg + ezetimibe 10mg reduced major atherosclerotic events by 16% in advanced CKD.
• Statin benefit is attenuated at very low eGFR and has limited benefit in dialysis patients (4D study, AURORA trial negative).
• Statins should NOT be initiated in dialysis patients but should be continued if already on them. (NKF Primer 8e; Comprehensive Clinical Nephrology 7th Ed.)

H. Anemia Management

• Anemia in CKD-DM: multifactorial (EPO deficiency, reduced EPO sensitivity, inflammation, iron deficiency).
• Erythropoiesis-stimulating agents (ESAs): Correcting severe anemia reduces LVH; however, targeting normal hemoglobin with ESAs showed no mortality benefit in RCTs and may increase cardiovascular risk if Hb is normalized (TREAT trial).
• HIF-PH inhibitors (e.g., roxadustat): Emerging agents for CKD anaemia, stimulate endogenous EPO production.

I. Additional Management

Key Evidence Summary

Recent update (2025): A Cochrane meta-analysis (PMID 39963952) confirms GLP-1 RAs reduce kidney and cardiovascular outcomes in patients with CKD + diabetes. A 2026 individual patient-level meta-analysis (PMID 41183334) reaffirmed albuminuria and proteinuria as powerful markers of both kidney and cardiovascular disease risk.